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ABSTRACT
The period of immune deficiency following bone marrow transplantation (BMT) results in a susceptibility to
opportunistic infections and remains a growing obstacle in improving the efficacy of BMT. Neuroendocrine
hormones have been shown to affect numerous immunologic and hematologic responses after in vivo admin-
istration. We investigated whether neuroendocrine hormones, notably prolactin (PRL), could be administered
after BMT and result in improved immunologic recovery. Mice were given lethal total body irradiation
followed with a congeneic or a syngeneic BMT. Some groups then received recombinant human PRL (rhPRL)
daily for 3 weeks. Effects on immune reconstitution and function were then monitored. The results show that
PRL could increase thymic cellularity and donor T-cell reconstitution after congeneic BMT. Increases in B
cells and myeloid progenitors were also observed. Mitogenic responses by both T and B cells were observed
after PRL treatment. These results suggest that PRL may be of use to promote immune and myeloid
reconstitution after BMT.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
Autologous bone marrow transplantation (BMT)
is currently used in the treatment of a variety of
neoplastic diseases. However, there are several prob-
lems associated with autologous BMT (ABMT). The
period of bone marrow aplasia leaves patients at risk
for opportunistic infections, and the immunosuppres-
sion caused by the cytotoxic therapy results in a
greater risk of tumor recurrence [1]. Cytokines such
as granulocyte colony-stimulating factor (G-CSF)
and granulocyte-monocyte colony-stimulating factor
(GM-CSF) are currently used to accelerate neutrophil
recovery post-BMT [2,3]. However, systematic ad-
ministration of these cytokines are associated with
signiﬁcant toxicities including ﬂu-like symptom, bone
pain, fatigue, and microvascular leaking syndrome
[4,5]. Importantly, these cytokines are not associated
with the promotion of immunologic recovery. There-
fore, agents need to be found that may be used alone
or in combination with G-CSF or GM-CSF for ac-
celerating the hematopoietic and immunologic recon-
stitution to decrease the dosage or to be used in place
of G-CSF or GM-CSF for shortening the period of
bone marrow aplasia and immunodeﬁciency after
ABMT.
It is known that differentiation and development
of various blood cell lineages from hematopoietic pro-
genitor cells and coordination of host immune re-
sponse are regulated by a group of cytokines. The
receptors for these factors have been grouped in a
large family of structural-related molecules including
IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, GM-CSF, G-CSF,
M-CSF, erythropoietin (Epo), prolactin (PRL), and
growth hormone (GH), which bind to distinct but
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related receptors [6]. Because of the structural simi-
larities between adenopituitary hormones (GH and
PRL) and conventional hematopoietic cytokines, GH
and PRL had been shown to exert many immunohe-
matopoietic-promoting effects [7-9]. Speciﬁc depres-
sion of PRL release induced by bromocriptin is asso-
ciated with decreased T-cell function and the response
of T cells in vitro is depressed in the presence of
anti-PRL antibodies [10]. Prolactin increased the pro-
liferating response of NK, T cells, and B cells to
mitogen. We have found that PRL administration
increased the antigen-speciﬁc proliferation of lymph
node T cells of both normal and dwarf mice [8] as well
as reversed the anemia and myelosuppression induced
by azidothymidine [11]. Here, we wanted to further
address the effects of PRL treatment on hematopoi-
etic and immunologic recovery following syngeneic or
congenic BMT (SBMT) in mice, affecting multiple
hematopoietic lineages at various stages of differenti-
ation. Therefore, recombinant human PRL (rhPRL)
may be of potential clinical use after high-dose che-




BALB/c, C57BL/6 (Ly5.1) mice, and C57BL/6
(Ly5.2) mice were obtained from the Animal Produc-
tion Area (National Cancer Institute at Frederick,
Frederick, MD). Mice were 8 to 12 weeks of age at the
initiation of treatment. Animal care was provided in
accordance with the procedures outlined in the
“Guide for the Care and Use of Laboratory Animals”
(National Institutes of Health Publication No. 86-23,
1985).
Bone Marrow Transplantation
Recipient BALB/c mice received 850 cGy and
C57BL/6-Ly5.1 mice received 950 cGy total body
irradiation from a 137Cs irradiation source. BALB/c
mice then received 1  106 syngeneic bone marrow
cells and C57BL/6 mice received 1  106 C57BL/6-
Ly5.2 congenic bone marrow cells intravenously (IV).
Experiments consisted of 4 to 5 mice per group at each
time point and each experiment was performed 3 to 4
times.
Hormone Treatment
BALB/c mice received 10 g rhPRL/0.2 mL
(Genzyme Corporation, Framingham, MA) in Dul-
becco’s phosphate buffered saline (DPBS) by intra-
peritoneal injection 3 times per week for 3 weeks
beginning at day 0 after BMT. C57BL/6 mice re-
ceived 50 g rhPRL/0.2 mL in DPBS 5 times per
week for 3 weeks beginning at day 0 after BMT. Mice
were weighed weekly. Immunologic and myeloid re-
covery was assessed at days 7, 14, 28, and 42 post-
BMT. The cells of the thymus, spleen, and femur,
were analyzed for cellularity, hematopoietic progeni-
tor assays, mitogen assays, and ﬂow cytometric anal-
ysis for immune markers.
Cellularity Analysis
Cell suspensions were prepared in RPMI-1640
media containing 10% fetal bovine serum, 1% peni-
cillin/streptomycin, and 2 mmol/L L-glutamine. Bone
marrow cells were ﬂushed from the femurs and single-
cell suspensions were obtained using a syringe and
22-gauge needle. Single-cell suspensions were pre-
pared from the spleens and thymi by mechanical dis-
sociation. The cellularities of bone marrow and
spleens were assayed using a particle counter (Beck-
man Coulter, Hialeah, FL).
Hematopoietic Progenitor Colony Assays
Spleen cells and bone marrow cells (BMCs) were
washed and suspended in Iscove’s modiﬁed Dulbec-
co’s medium with 15% FBS, 2 mmol/L L-glutamine,
5  10-5 M 2-mercaptoethanol, 100 U penicillin/mL,
and 100 g streptomycin/mL. Colony-forming unit
granulocyte-macrophage (CFU-GM) and burst-form-
ing unit-erythroid (BFU-e) were determined by plat-
ing cells in 1.1% methylcellulose (Fisher Scientiﬁc) in
triplicate 35-mm petri dishes at a concentration of 1
105 spleen cells or 5  104 BMC per plate. Colony
formation was stimulated with predetermined doses of
cytokines including 10 ng/mL each of recombinant
murine GM-CSF (rmGM-CSF) and interleukin-3
(rmIL-3) (Peprotech, Rocky Hill, NJ), and 5 U/mL
Epo (Stem Cell Technologies, British Columbia,
Canada). Plates were incubated at 37°C for 7 days in
5% CO2with 100% humidity. Colonies were deﬁned
as aggregates of more than 50 cells. Colonies that
contained only red cells in single or multiple bursts
were scored as BFU-e. Colonies consisting of only
white cells containing granulocytes and/or macro-
phages were scored as CFU-GM.
Flow Cytometry Analysis
Thymic, splenic, and bone marrow single-cell sus-
pensions were individually prepared and analyzed by
double-color ﬂow cytometry analysis. Reagents used
included ﬂuorescein isothiocyanate–labeled anti-CD4
(RM4-5), GR-1 (RB6-8C5), CD45.1 (Ly5.2; A20),
phycoerythrin-labeled anti-CD8 (53-67), B220 (RA3-
6B2), CD11b (M1/70), biotin-anti–CD4 (RM4-5),
streptavidin-cychrome obtained from Pharmingen-
Becton Dickinson (Mountain View, CA), and ﬂuores-
cein isothiocyanate–goat anti-mouse IgM (Southern
Technologies Associates, Birmingham, AL). 1 
106cells were resuspended in staining buffer (DPBS
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containing 5% FBS) and incubated with antibody for
30 minutes at 4°C. After washing with staining buffer,
cells were ﬁxed in 1% paraformaldehyde and analyzed
on a FacScan ﬂow cytometer (Becton-Dickenson).
Each ﬂuorescence study included directly labeled iso-
type controls of the appropriate rat immunoglobulin
isotype.
Splenic Mitogen Proliferation Assays
Splenocytes (1 106/200 L) per well were plated
in 96-well ﬂat-bottomed plates in triplicate and incu-
bated at 37°C in 5% CO2 with 0.1 to 25 g/mL of
concanavalin A (ConA) or lipopolysaccharide (LPS)
(Sigma, St. Louis, MO). After 3 days of culture at
37°C, the cultures were pulsed with 1 Ci of 3H-
thymidine (ICN, Aurora, OH) per well and incubated
for an additional 12 hours. Cells were then harvested
onto glass ﬁber ﬁlters and the incorporated radioac-
tivity was quantiﬁed by a scintillation counter (Wallac
LKB, Turku, Finland).
Statistical Analysis
All experiments were performed 3 times with 4 to
5 mice per group. Data are presented as the mean 
SEM. A Student’s t-test was performed to determine
statistical signiﬁcance of differences between experi-
mental groups and control groups.
RESULTS
rhPRL Promotes Hematopoietic Progenitor
Recovery in Mice after Syngenenic Bone Marrow
Transplantation
To determine whether rhPRL could enhance he-
matopoietic engraftment and reconstitution following
SBMT, BALB/c mice were injected with 10 g of
rhPRL 3 times per week for 3 weeks after myeloabla-
tive irradiation and BMC transfer. This dose and
schedule of rhPRL administration has been shown to
counteract the myelosuppressive activity of azidothy-
midine in mice [11]. Animals were assessed at weekly
intervals for hematopoietic recovery. Toxicity was not
observed at any level of rhPRL given in these studies.
Administration of rhPRL did not signiﬁcantly alter
spleen and bone marrow cellularity in recovering mice
with the exception of day 14 posttransplantation for
both tissues and day 28 in the spleen (data not shown).
rhPRL administration did result in signiﬁcant in-
creases in bone marrow hematopoietic progenitor cell,
including myeloid (CFU-GM) and erythroid (BFU-e)
progenitor content at various time-points after SBMT
compared with the vehicle control treated group (Fig-
ure 1). The CFU-GM content of bone marrow sig-
niﬁcantly increased 1.9-fold at day 21 (P  .05) after
SBMT (Figure 1A). Femoral BFU-e were signiﬁcantly
increased at days 21 (P  .001), 28 (P  .05), and 42
(P  .001) post-SBMT by 1.6- to 3.2-fold compared
with PBS control-treated mice at the various time
points (Figure 1B). Splenic hematopoietic progenitor
cell content was signiﬁcantly increased in mice receiv-
ing rhPRL at day 7 (P  .05) to day 42 (P .01)
(CFU-GM), and day 7 (P  .05), 21 (P  .01), 28 (P
 .001), and 42 (P  .01) (BFU-e) after SBMT (Fig-
ure 2). In both the rhPRL and PBS control-treated
animals, peak CFU-GM (Figure 2A) and BFU-e (Fig-
ure 2B) recovery in spleen occurred on day 14 post-
BMT. Thus, the results indicated that treatment with
rhPRL promoted BMC engraftment through im-
proved development and expansion of hematopoietic
progenitor cells.
rhPRL Improves B-Cell Lineage Development and
Function
A role for PRL on immune function has been
suggested, but hormonal effects have been difﬁcult to
Figure 1. Effects of rhPRL on bone marrow hematopoietic pro-
genitor content after syngeneic bone marrow transplantation.
BALB/c mice received 850 cGy and 1  106 syngeneic BMC IV.
The mice then received PBS or 10 g rhPRL 3 times per week IP
for 3 weeks. Hematopoietic progenitor content was analyzed at
various time-points post-SBMT. Progenitor cell CFU-GM (A) and
BFU-e (B) assays were performed. Colonies per femur were calcu-
lated from the colony frequency and BM cellularity. There were 4
mice for per group at each time point. Data shown are from 3
separate experiments. *  P  .05; **  P  .01; ***  P  .001
compared with PBS-treated controls.
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demonstrate with isolated cells and there are little data
showing rhPRL effects on B-cell development and
function in vivo. There has been a recent report that
PRL could affect B-cell function [12]. We focused on
the content of pre-B cells (B220 IgM) and B cells
(B220 IgM) in the bone marrow and spleen after
rhPRL treatment following SBMT. The results show
that pre-B cells in the bone marrow are signiﬁcantly
increased in rhPRL treatment mice after SBMT at day
21 (Figure 3A). The absolute number of pre-B cells in
the bone marrow increased 1.6 fold. It was also noted
that B cells (B220/sIgM cells) were signiﬁcantly
increased in the bone marrow at day 28 (P .05) after
SBMT compared with PBS control (Figure 3B).
Following BMT, the spleen is an extramedullary
site for both B lymphopoesis and myelopoiesis. Pre-B
cells peaks at day 14 posttransplantation in animals
that received either rhPRL or PBS followed by a
marked drop off in B-cell production as homeostasis is
achieved. B-cell content in the spleen was signiﬁcantly
(P  .05) increased in PRL-treated mice compared
with PBS treated mice (Figure 4A).
Splenic IgM B cells were signiﬁcantly increased
at day 21 (P .05) and day 28 (P .01). The absolute
number of IgM B cells in the spleen increased 1.4
fold at both time points in rhPRL treated mice, re-
spectively, compared with PBS-treated animals (Fig-
ure 4B). IgM B cells peak at day 28 in both treatment
groups. The results suggest that rhPRL accelerates
B-cell engraftment and differentiation. We also tested
B-cell function as measured by splenocyte response to
the mitogen LPS. C57BL/6-Ly5.1 mice received 950
Figure 2. Effects of rhPRL on splenic hematopoietic progenitor
after syngeneic bone marrow transplantation. BALB/c mice re-
ceived 850 cGy followed by infusion of 1 million syngeneic BMC
IV. The mice then received PBS or 10 g rhPRL 3 times per week
IP for 3 weeks. Mice were euthanized at various time-points post
SBMT. Progenitor cell CFU-GM (A) and BFU-e (B) assays were
performed. Colonies per spleen were calculated from the colony
frequency and splenic cellularity. There were 4 mice for per group
at each time point. Data shown are from 3 separate experiments.
*  P  .05; **  P  .01; ***  P  .001 compared with
PBS-treated controls.
Figure 3. Effects of rhPRL on bone marrow B-cell progenitor and
mature B-cell content after syngeneic bone marrow transplantation.
BALB/c mice received 850 cGy followed by infusion of 1 million
syngeneic BMC IV. The mice then received PBS or 10 g rhPRL
3 times per week IP for 3 weeks. Mice were euthanized at day 21 and
day 28. Bone marrow cells were labeled and analyzed with 2-color
ﬂow cytometry to determine (A) pre–B cells and (B) B cells. There
were 4 mice for per group at each time point. Data shown are from
3 separate experiments. *  P  .05 compared with PBS-treated
controls.
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cGy total body irradiation followed by infusion of 1
million C57BL/6-Ly5.2 congenic bone marrow cells.
The relative frequency of B cells (donor and host
derived) did not differ signiﬁcantly between rhPRL
and control treated groups (data not shown). As shown
in Figure 5, a signiﬁcant (P  .01 at maximal peak of
10 g/mL) dose-dependent enhancement of 3H-thy-
midine incorporation was observed in the splenocytes
stimulated by LPS in mice at day 21 after rhPRL
administration in SBMT. The data presented here
show that PRL can improve the development and
function of B-cell lineage from hematopoietic progen-
itor cells after BMT.
rhPRL Improves T-Cell Lineage Development and
Function
T-cell recovery in particular is critical after BMT
in adults [13]. To determine if rhPRL administration
could enhance donor T-cell engraftment, we used a
congenic BMT (CBMT). C57BL/6 Ly5.2 BMC were
transferred into congenic Ly 5.1 mice. After total
body irradiation, our initial studies in SBMT BALB/c
mice and 10 g rhPRL given 3 times per week showed
minimal effects in T cells (data not shown). There-
fore, the dose was increased to 50 g 5 times per week.
Thymus cellularity was signiﬁcantly increased at day
14 (P .05) and day 60 (P .01) after CBMT (Figure
6). The donor-derived T-cell content of the spleen
(CD4 T cells) was also signiﬁcantly increased at day
21 (P .05) and day 28 (P .05) after CBMT (Figure
7) and donor derived CD8 T cells were signiﬁcantly
(P  .05) elevated in PRL treatment on day 21, sug-
gesting that T-cell development after SBMT was ac-
celerated by rhPRL administration. In addition, we
examined the T-cell function in mice receiving rhPRL
after CBMT. We found that, in addition to increased
numbers of donor-derived T cells, the splenocytes
from mice receiving rhPRL showed signiﬁcantly
(P  .001 at maximal peak of 1 g/mL) greater pro-
liferating response to the T-cell mitogen, concanava-
lin A, at day 21 posttransplantation (Figure 8). This
difference was observed despite the observation that
the relative frequency of CD3 cells (donor and host
derived) did not differ signiﬁcantly between rhPRL
and control treated groups (data not shown). These
data verify that rhPRL may improve the development
and function of T-cell lineage after CBMT.
DISCUSSION
Prolactin, initially described as a peptide hormone
secreted by the anterior pituitary, has been shown to
exert a variety of biological effects in vivo and has been
Figure 4. Effects of rhPRL on splenic B-cell progenitors and
mature B-cell content after syngeneic bone marrow transplantation.
BALB/c mice received 850 cGy followed by infusion of 1 million
syngeneic BMC IV. The mice then received PBS or 10 g rhPRL
3 times per week IP for 3 weeks. Mice were euthanized at various
time-points and spleen cells were labeled and analyzed with 2-color
ﬂow cytometry to determine (A) pre–B cells and (B) B cells. There
were 4 mice for per group at each time point. Data shown are from
3 separate experiments. *  P  .05; **  P  .01; compared with
PBS-treated controls.
Figure 5. Effects of rhPRL on splenic B-cell mitogen responsive-
ness after congenic bone marrow transplantation. C57BL/6-Ly5.1
mice received 950 cGy total body irradiation followed by infusion of
1 million C57BL/6-Ly5.2 congenic bone marrow cells. The mice
then received PBS or 50 g rhPRL 5 times per week IP for 3 weeks.
Mice were euthanized at day 21 and spleen cells proliferative re-
sponse to LPS was measured as described in “Materials and Meth-
ods.” Data shown are from 3 separate experiments. *  P  .05;
**  P  .01 compared with PBS-treated controls.
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suggested to also exert effects on hematopoietic and
immune cell types [8]. We previously reported that
ovine PRL could augment peripheral immune func-
tion in pituitary hormone-deﬁcient dwarf mice [14]
and PRL administration increased numbers of hema-
topoietic progenitors in mice stressed by azidothymi-
dine, a myelotoxic drug [11]. The data presented sup-
port and extend these ﬁndings. The results indicate
that administration of rhPRL to mice after BMT
enhances hematopoietic reconstitution as determined
by increased hematopoietic progenitor cell content of
bone marrow and spleen, and numbers of granulo-
cytes, T-cell progenitors, and B-cell progenitors by
ﬂow cytometric phenotypic analysis, accelerated re-
covery of red blood cells in the peripheral blood, and
improved splenic T-cell and B-cell mitogen responses.
We have reported that GH and PRL exerted dif-
ferential effects on murine T-cell development and
function in neuroendocrine hormone-deﬁcient dwarf
mice [15], which have been reported to have deﬁcien-
cies in T-cell development and function [16]. In con-
trast to the thymopoietic effects of GH, ovine PRL
administration resulted in accelerated thymic atrophy
in these mice [15]. Interestingly, PRL administration
had no effect on thymic size in normal mice and
thymic recovery was more obvious at the 50 g PRL
dose than the 10 g dose, suggesting that lack of other
hormones in the dwarf mouse made it susceptible to
the inhibitory effects of PRL. We speculate that there
are important differences in immunohematopoiesis
between neuroendocrine hormone-deﬁcient dwarf
mice and lethally irradiated and reconstituting mice.
Dwarf mice have low circulating levels of pituitary
hormones because of the lack of acidophilic anterior
cells, but lethally irradiated mice do produce these
hormones; therefore, we believe multiple pituitary
hormones may inﬂuence hematopoiesis. While the
mechanism by which rhPRL promotes thymopoiesis
in either of these models is not known, PRL receptors
are found on both thymocytes [17] and thymic epith-
lelium [18]. Prolactin administration post-BMT may
induce sustained changes in the thymic stroma, which
result in enhanced and prolonged thymopoiesis. In
addition to effects on thymus, we also found that PRL
exerted effects on B-cell development and function in
vivo after BMT. It is also important to note that the
hematopoietic growth-promoting effects of rhPRL
Figure 6. Effects of rhPRL on donor engraftment in thymus after
congenic bone marrow transplantation. C57BL/6-Ly5.1 mice re-
ceived 950 cGy total body irradiation. Then received 1  106con-
genic bone marrow cells from C57BL/6-Ly5.2 donor IV. The mice
then received PBS or 50g rhPRL 5 times per week IP for 3 weeks.
Thymuses were harvested at various time-points post-CBMT. Do-
nor cell engraftment was calculated from the CD45.1 cell fre-
quency and cellularity. Mean engraftment and standard error was
determined with 4 to 5 mice per group. Data shown are from 3
separate experiments. *  P  .05; **  P  .01 compared with
PBS-treated controls.
Figure 7. Effects of rhPRL on splenic T-cell subsets after congenic
bone marrow transplantation. C57BL/6-Ly5.1 mice received 950
cGy total body irradiation followed by infusion of 1 million C57BL/
6-Ly5.2 congenic bone marrow cells. The mice then received PBS
or 50 g rhPRL 5 times per week IP for 3 weeks. Mice were
euthanized at day 21 and day 28. Splenocytes were labeled and
analyzed with triple-color ﬂow cytometry to determine donor ori-
gin and T-cell subsets. There were 4 mice per group at each time
point. *  P  .05 compared with PBS-treated controls. Data
shown are from 3 separate experiments.
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administration after SBMT occurred at a dose and
schedule that did not result in toxicity or signiﬁcant
weight gain. It was reported that systemic administra-
tion of IL-11 after SBMT [19], administration of IL-6
following chemotherapy [20,21], or treatment with
IL-12 also increases hematopoietic recovery [22,23].
In a clinical setting, systemic administration of these
cytokines may produce toxic side effects [19-23].
Therefore, the advantage of using rhPRL in combi-
nation with other cytokines after ABMT may be of
beneﬁt in the reduction of toxicity after systemic ad-
ministration.
The mechanism by which rhPRL promotes he-
matopoietic and immune reconstitution after
SBMT is not yet clear. The stimulatory effects on
hematopoietic progenitor cells may be because of its
ability to exert either direct proliferative effects on
the progenitor cells or indirect effects by improving
the responsiveness of the marrow cells to growth-
promoting reagents. There is mixed evidence from
in vitro experiments to support the suggestion that
PRL acts directly on hematopoietic progenitor via
PRL receptors [24,25]. The PRL receptor is ex-
pressed on lymphoid and hematopoietic tissue
[26,27]. Engagement of PRL with its receptor on a
very early population of hematopoietic progenitors
promotes the expression of an Epo receptor and
thus improves the responsiveness to Epo [24]. The
PRL receptor rescues Epo-R/ erythroid progen-
itors and replaces Epo-R in a synergistic interaction
with c-kit [28]. Prolactin improves human CD34
colony development in the semi-solid agar colony
assay system [24] and enhances erythropoiesis and
myelopoiesis in vitro [25]. Increasing of colony for-
mation was observed with 25 to 50 ng/mL of PRL
in vitro [29]. Formation of BFU-e colonies from
GM-CSF, IL-3, and Epo-stimulated CD34 pro-
genitors was signiﬁcantly inhibited by an anti-PRL
antibody [25]. We report here that mice receiving
rhPRL exhibited signiﬁcant increases in hematopoi-
etic progenitor cell (CFU-GM, CFU-Mix, and
BFU-e) content and resulted in signiﬁcant increases
in red blood cells and granulocytes after SBMT.
Results suggest that PRL affects multiple hemato-
poietic lineages at various stages in differentiation.
It was recently reported that human peripheral
blood granulocytes express PRL mRNA in vitro
[30]. Macrophages and monocytes could mediate
the effects of PRL on hematopoietic progenitors
through secretion of cytokines and chemokines.
The activities of macrophages are enhanced by PRL
[31]. We observed that PRL increased the number
of granulocytic and monocytic progenitors (CFU-
GM) in mice after SBMT; indirect feedback
through monocytes may explain the indirect effects
of PRL on hematopoiesis. We also found that PRL
exerted effects on B-cell development and function,
further conﬁrming the results that expansion/differ-
entiation of normal BM pro-B cells was stimulated
by PRL in vitro and in vivo [32]. Human GH has
also been shown to be capable of binding the mu-
rine PRL receptor [33], and some of the in vivo
effects of rhGH may be caused by this binding
capability. Additionally, it is known that many of
the growth-promoting effects of rhGH are medi-
ated by IGF-1. IGF-1 stimulates rat PRL gene
expression [34]. Studies have determined that
IGF-1 promotes hematopoiesis after in vivo admin-
istration [35]. Growth hormone has also been
shown to exert these effects [7] and may exert these
effects in a manner similar to PRL. It is unclear that
the effects of PRL on immunologic and hematopoi-
etic development are direct or indirect.
Prolactin has been postulated to have signiﬁcant
effects on the immune system [36], but more work
needs to be performed to determine the effect of
rhPRL on long-term immune reconstitution after
SBMT. When ABMT is used in the treatment of
cancer, recurrence of the underlying malignancy
remains a major cause of treatment failure. There-
fore, caution must be taken if using rhPRL to pro-
mote hematopoietic recovery in treating a cancer
patient with ASBMT, when ABMT is used for the
treatment of cancer because of potential effects of
rhPRL on tumor growth [37]. However, the present
report suggests that the pleiotropic actions of rh-
PRL on various stages and lineages of hematopoi-
etic cell growth after systematic administration may
be of considerable use to promote hematopoietic
recovery after myelosuppressive therapy, and to
Figure 8. Effects of rhPRL on splenic T-cell mitogen responsive-
ness after congenic bone marrow transplantation. C57BL/6-Ly5.1
mice received 950 cGy total body irradiation followed by infusion of
1 million C57BL/6-Ly5.2 congenic mice then received PBS or 50
g rhPRL 5 times per week IP for 3 weeks. Mice were euthanized
at day 21 and spleen cells proliferative response to ConA was
measured, as described in “Materials and Methods.” Data shown are
from 3 separate experiments. *P  .05; ***P  .001 compared with
PBS-treated controls.
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stimulate the function of immune competent cell as
adjuvant immunotherapy.
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